Euretos has developed in silico methodologies for Biomarker Discovery: the identification of (alternative) biomarkers for a specific type of purpose ( e.g. mechanism, outcome, pharmacogenomic, toxicity, diagnostic) and type (e.g. genomic, proteomic, metabolomic, lipidomic, glycomic). Our focus is especially in biomarkers that are disease (stage) related as we use detailed molecular disease models to identify the most distinctive and bio-available markers.
High Level Approach
Conceptually, our approach consists of two steps. In the first step, we will construct an in silico molecular disease model for the indication with which the biomarker is identified, based on public and/or private data.
A molecular disease model identifies for a specific disease the dysregulated genes, proteins and pathways as well as the underlying cell types and interactions between cell types that are dysregulated, to the extent that available data allows this. This provides the specific disease context for which the biomarker can be identified.
In the second step we use the disease model to identify genes, proteins or metabolites that are strongly correlated with the molecular mechanism(s) that are dysregulated in the disease of interest.
Since the disease model is cell-type specific, the biomarkers can also be specific to cell types and tissues. Depending on the purpose and type of biomarker specific requirements (e.g. secretion, metabolic interaction) are assessed in more detail.
Euretos will provide a list of biomarkers ranked using our biomarker score. It builds the case for several biomarkers elaborates on the molecular drivers for each of the candidates and on the various evaluation criteria.
For three selected biomarkers, we will provide a description of its relation to the disease and perturbation model, as well as the evidence supporting the biomarker ranking in a human-readable report in the form of a research paper. The report will contain references and links to publicly available knowledge and data supporting the premise of the three biomarker candidates.
Furthermore, the customer will be able to review the target/indications with the gene disease page and the gene detail page in the Euretos AI platform for a 1-month period